Antibody responses to *Haemophilus influenzae* type b conjugate vaccine in sickle cell disease

D Goldblatt, M Johnson, J Evans

Abstract

**Objective** — To investigate the immunogenicity of *Haemophilus influenzae* type b (Hib) conjugate vaccines in children with sickle cell disease.

**Design** — Open study.

**Setting** — Haemoglobinopathy clinic.

**Subjects** — Children with homozygous haemoglobin SS disease (HbSS), sickle haemoglobin C disease (HbSC), and sickle-β thalassaemia disease (HbS-βThal).

**Interventions** — Children over the age of 2 years received a single dose of Hib-tetanus toxoid conjugate vaccine (PRP-T). A second important pathogen is *Haemophilus influenzae* type b (Hib) which accounts for a disproportionately large amount of infection in children of all ages with sickle cell disease compared to their healthy counterparts. This risk has been estimated as 1/81 person years for children < 5 years of age with sickle cell disease, which is two to three times higher than the risk in normal children under 5 years of age. Within sickle cell disease the risk for invasive bacterial infection varies according to the form of the disease, those with HbSS being at higher risk than those with sickle haemoglobin C disease (HbSC). Whiile splenic function is thought to be important in protecting individuals from invasive bacterial infection, the susceptibility of children with sickle cell disease to such infections cannot be attributed solely to splenic dysfunction and remains poorly understood. Before the introduction of conjugated Hib vaccines, pure Hib capsular polysaccharide vaccines were evaluated in children with sickle cell disease. They were shown to be non-immunogenic in children under the age of 18 months and poorly immunogenic in those from 18 months to 5 years. Hib conjugate vaccines, in contrast, have been shown to be highly immunogenic in healthy infants as young as 2 months of age and their introduction into the routine infant immunisation programme has resulted in a dramatic decline in the incidence of invasive Hib disease in the UK.

As a result of the increased risk of bacterial infection in sickle cell disease, immunisation to protect children from both *S pneumoniae* and Hib infection is recommended in the USA by the American Academy of Pediatrics and the Centers for Disease Control, Atlanta. However, the UK Department of Health makes no mention of sickle cell disease in its list of recommendations for Hib conjugate vaccine, but does recommend pneumococcal vaccination in this group. Routine Hib conjugate vaccination introduced in the UK in 1992 was targeted to children below 5 years of age; hence children born before 1988, including those with sickle cell disease, will have remained unimmunised.

The aim of this study was to establish baseline anti-Hib polysaccharide antibody titres in a group of children with sickle cell disease, to evaluate the immunogenicity of a single dose of...
**Table 1** Geometric mean anti-Haemophilus influenzae type b (Hib) polysaccharide and polylactide capsule (PRP) IgG titres post Hib-tetanus toxoid conjugate vaccination

<table>
<thead>
<tr>
<th>Titre</th>
<th>HbSS</th>
<th>HbSC</th>
<th>HbS-βthal</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>55</td>
<td>16</td>
<td>6</td>
</tr>
<tr>
<td>Pre</td>
<td>0.92 (0.85 to 1.20)</td>
<td>1.18 (0.63 to 2.18)</td>
<td>1.19 (0.26 to 5.55)</td>
</tr>
<tr>
<td>Post</td>
<td>36.7* (25.1 to 52.9)</td>
<td>91.12* (32.7 to 254.4)</td>
<td>34.82 (9.41 to 128)</td>
</tr>
</tbody>
</table>

Children are divided into those with homozygous sickle cell disease (HbSS), sickle-haemoglobin C disease (HbSC), and sickle-β* thalassaemia disease (HbS-βthal). Anti-polysaccharide and polylactide capsule (PRP) IgG levels were measured by enzyme linked immunosorbent assay in serum obtained 4-8 weeks postimmunisation.

* Student's t test: HbSS vs HbSC, p = 0.026.

an Hib conjugate vaccine in such children, and to compare the vaccine immunogenicity in children with different forms of sickle cell disease whose risk varies for invasive Hib disease.

**Methods**

**PATIENT POPULATION**

Children over 2 years of age with the diagnosis of HbSS, HbSC, or sickle-β* thalassaemia disease (HbS-βthal) were eligible for this study and were recruited from a population of children attending a sickle cell disease clinic at the Queen Elizabeth Hospital, Hackney, London between January 1993 and January 1994. Ethics approval for the study was obtained locally and informed written consent was obtained for each participant. Children who had been given previous Hib vaccines were excluded from the study, as were children under the age of 2 years who received their vaccination from general practitioners. Immunisation was delayed if children were febrile at the time of consultation.

**PROCEDURES**

Study participants received 0.5 ml intramuscularly of a licensed Hib-tetanus toxoid conjugate vaccine (ActHib, Merieux UK). Parents were asked to keep a record of adverse events for one week following immunisation. Information on adverse events was either telephoned to the study nurse or obtained at the follow up visit. Serum samples were obtained before and between one and two months after immunisation and stored at −70°C before analysis.

**SEROLOGICAL STUDIES**

Total antibody to PRP was assayed by enzyme linked immunosorbent assay (ELISA) as previously described. Antibody levels in the unknown serum were derived from the standard curve and expressed as μg/ml. The standard curve was derived from an internal standard serum calibrated against a reference serum obtained from the US Food and Drug Administration Office of Biologics, Research and Review (kindly supplied by Dr Carl Frasch), which contains 60.9 μg/ml of anti-PRP IgG. The assay was compared with a similar assay at another centre (Oxford, UK [see 10]) and the correlation between the two assays for pairs of infant sera was 0.97 (H Griffiths, personal communication). Accepted titres relating to short and long term protection from invasive Hib disease are 0.15 and 1.0 μg/ml respectively.

**RESULTS**

Seventy seven children were studied (44 males, 33 females), of whom 55 had HbSS, 16 had HbSC, and six had HbS-βthal. The mean age of the children studied was 8.65 years (range 2 to 16.42 years). The mean age for HbSS children was 8.75 years (2 to 16.42), for HbSC 7.9 years (2.08 to 15.75), and for HbS-βthal 9.21 years (6.25 to 14.66). The majority of the children in the study were either of West African (n = 43) or Afro-Caribbean origin (n = 30).

The vaccine was well tolerated, with no immediate reactions. Only one vaccinee reported swelling and erythema at the site of the injection lasting for more than 48 hours.

Analysis of the prevaccination titre of anti-PRP IgG for the group as a whole showed that 12% (9/77) had an antibody titre ≤ 0.15 μg/ml, 33% (25/77) had an antibody titre > 0.15 and ≤ 1.0 μg/ml, while 55% (43/77) had an antibody titre > 1.0 μg/ml. Following vaccination all study participants achieved a titre of anti-PRP antibody of > 1 μg/ml. Analysis of the correlation between age and the prevaccination anti-PRP titre showed there to be no positive correlation (r² = 0.02) for the group as a whole. In addition there was no positive correlation between the age of the vaccinee and the magnitude of the postvaccination responses (r² = 0.01).

The geometric mean prevaccination antibody titre for the group as a whole was 1.0 μg/ml (95% confidence interval (CI) 0.75 to 1.34) and postvaccination, 45.2 μg/ml (95% CI 31.6 to 64.8). The geometric mean titre after vaccination was independent of ethnic background (p = 0.42). Interesting differences were noted for the subgroups of sickle cell disease (table 1). Before vaccination there was no difference between the geometric mean antibody titres for the three groups. However, after vaccination children with HbSC had a higher geometric mean antibody titre than the children with both HbS-βthal (p = 0.1) and HbSS (p = 0.026). All groups, however, achieved mean levels well above the accepted minimum protective level.

**DISCUSSION**

Children with sickle cell disease are unduly susceptible to infection with encapsulated bacteria, and young children with sickle cell disease are particularly at risk. The susceptibility of this group stratifies according to the type of sickle cell disease. Children with HbSS are most at risk, while those with HbSC appear to be much less susceptible. The basis for this difference is poorly understood, although it is clear that splenic function is lost earlier in HbSS than in HbSC. Fatal infections with encapsulated organisms in children with
H. influenzae type b conjugate vaccine in sickle cell disease

HbSC have, however, been described and their risk of invasive infection is said to be higher than those of the general population. Forty per cent of the children in this study had a prevaccination titre of < 1.0 µg/ml, the level associated with long term protection against sickle cell disease. While the risk of invasive Hib infection in the healthy population declines sharply with age and is rare after the age of 5, it is likely that children with sickle cell disease remain at risk, especially if splenic function is compromised. Half the children in this study were therefore potentially at risk of infection on the basis of their antibody titres. Following a single dose of PRP-T, 100% had a level of anti-PRP IgG > 1.0 µg/ml and the postvaccination geometric mean titre for the group as a whole was very close to that published for healthy adults following Hib conjugate vaccine and to that published for children with sickle cell disease resident in the USA.

Several studies have sought a difference in the immunogenicity of conjugate vaccines in HbSS versus HbSC, although the numbers of children studied have been small and no significant differences have been detected. Frank et al compared the immunogenicity of conjugated versus unconjugated PRP. While 46 HbSS and 18 HbSC patients were studied, the groups were divided to compare the different vaccine formulations and no statistical differences were detected between the two groups. Recently, Marcinak et al in a follow up study of antibody persistence following Hib conjugate vaccination, have been unable to detect a difference in the GMT of anti-PRP titres in children with HbSS compared to Hb SC disease nor any difference in the rate of anti-PRP antibody decline. In our study, children with a diagnosis of HbSC mounted a significantly higher anti-PRP IgG response than those with HbSS. While this higher titre correlates with a reduced susceptibility to invasive Hib disease in HbSC compared to HbSS, all children in the study mounted antibody responses greater than the long term protective anti-PRP level of > 1.0 µg/ml. This protective level was, however, derived from field studies of the Hib vaccine in normal individuals, and no equivalent protection data exist for immunodeficient individuals. It is therefore not clear whether the higher titre of antibody mounted by the children with HbSC is clinically relevant to protection. It is also not clear whether this higher level may be associated with prolonged persistence of antibody and this aspect of the immune response to PRP-T is the subject of ongoing study.

Of the children with a diagnosis of sickle cell disease who are over the age of 2 years and have not received Hib vaccines, up to one half may have an antibody level below that indicating long term protection. Such children make a vigorous antibody response to a single dose of PRP-T vaccine and hence we suggest that unimmunised individuals in this group should receive a single dose of a Hib conjugate vaccine, and this recommendation should be included in the indications for Hib vaccination. All infants born in the UK, including those with sickle cell disease, should be given three doses of Hib conjugate vaccines as part of the routine infant immunisation schedule.

We would like to thank all the staff of the Diagnostic Unit, Queen Elizabeth Hospital Hackney for help with this study, and Christina Pansato for technical help.
